Department of Preventive Medicine, College of Medicine, Chosun University, Gwangju, Republic of Korea
Department of Urology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea.
BMJ Open. 2022 Dec 20;12(12):e065924. doi: 10.1136/bmjopen-2022-065924.
Cancer screening guidelines should be based on the best available evidence, presenting both the benefits and harms of screening in a manner applicable to stakeholders. How the potential benefits and harms of screening are presented determine the intent of guideline developers and the delivery of recommendations. Therefore, we will systematically review the cancer screening guidelines for Koreans to evaluate the presentation and detailed ways of the benefits and harms of the recommended cancer screening practices.
To identify cancer screening guidelines for Koreans, we will search international electronic databases, including MEDLINE, Embase and domestic literature databases (Korean Studies Information Service System, Research Information Sharing Service, KoreaMED, Korean Medical Database, National Assembly Library and Korea Institute of Science and Technology Information) as well as guideline databases (Guideline International Network, National Institute for Health and Care Excellence, Turning Research Into Practice medical database, WHO guidelines and Korean Medical Guideline Information Center), from inception to November 2022. We will include cancer screening guidelines for healthcare practitioners and patients. Furthermore, we will focus on the most updated guidelines when multiple versions of guidelines are available for a specific intervention and cancer pairs from the same development group. Two reviewers will independently and in duplicate conduct reference screening and data extraction. Data will be extracted based on recommendations from each guideline and how their benefits and harms are presented. The general characteristics of cancer screening guidelines, including cancer type, recommended screening methods, certainty of evidence, direction and strength of recommendation, will be collected. In addition, we will obtain key information on the presentation of the benefits and harms of screening interventions, including quantification of their relative and absolute effects of screening interventions. Finally, our findings will be presented descriptively, and a summary of the results will be provided.
Ethics approval is not required as we will only use published materials. We will disseminate our findings through publication in peer-reviewed journals.
癌症筛查指南应基于现有最佳证据,以适用于利益相关者的方式呈现筛查的益处和危害。筛查的潜在益处和危害的呈现方式决定了指南制定者的意图和建议的实施。因此,我们将系统地审查韩国的癌症筛查指南,以评估推荐的癌症筛查实践中益处和危害的呈现方式和详细方法。
为了确定韩国的癌症筛查指南,我们将从一开始到 2022 年 11 月,在国际电子数据库(包括 MEDLINE、Embase 和国内文献数据库(韩国研究信息服务系统、研究信息共享服务、韩国医学数据库、国家医学图书馆和韩国科技信息研究所)以及指南数据库(国际指南网络、国家卫生与保健卓越研究所、将研究转化为实践医学数据库、世界卫生组织指南和韩国医学指南信息中心)中搜索韩国的癌症筛查指南。我们将包括针对医疗保健从业者和患者的癌症筛查指南。此外,当针对特定干预措施和来自同一开发小组的癌症对有多个版本的指南时,我们将重点关注最新的指南。两位审查员将独立地、重复地进行参考文献筛查和数据提取。将根据每个指南的建议以及它们的益处和危害的呈现方式提取数据。将收集癌症筛查指南的一般特征,包括癌症类型、推荐的筛查方法、证据的确定性、建议的方向和强度。此外,我们将获得有关筛查干预措施益处和危害呈现的关键信息,包括筛查干预措施相对和绝对效果的量化。最后,我们将以描述性方式呈现研究结果,并提供结果摘要。
由于我们仅使用已发表的材料,因此不需要伦理批准。我们将通过在同行评议期刊上发表来传播我们的研究结果。